{"name":"Napo Therapeutics, S.p.A.","slug":"napo-therapeutics-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Crofelemer Powder for Oral Solution","genericName":"Crofelemer Powder for Oral Solution","slug":"crofelemer-powder-for-oral-solution","indication":"Diarrhea-predominant irritable bowel syndrome (IBS-D)","status":"phase_2"}]}],"pipeline":[{"name":"Crofelemer Powder for Oral Solution","genericName":"Crofelemer Powder for Oral Solution","slug":"crofelemer-powder-for-oral-solution","phase":"phase_2","mechanism":"Crofelemer is a plant-derived inhibitor of the sodium glucose cotransporter 2 (SGLT2)","indications":["Diarrhea-predominant irritable bowel syndrome (IBS-D)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNZHliZDlJaTRKczZkUzg0dmlhNWstYjF4azZlNVd2cmJMMWk3RzhZcGJORHdpS0lDdGptQ2UyeXRod19lVWFMd0k2bVgzdmphS2dfY0MzREozUEpMWV9uaEIweFplM1NfOFVVbkJ6TDZLMk1MaWM3T096MmE3UGg2MjlzVUdOOGhmZ3EwZEhoczFWYjhHS0tVLXo5V0xIanIzX1R1Z1FlMktsZFNrc3NWcGtVZlQ4S0RvTWp6blNMa3VrcGIyLUd5LW80VEl4OGlaQlo2VXY0M0ZjOTNldGxqQ3BVYjg?oc=5","date":"2026-04-08","type":"regulatory","source":"ACCESS Newswire","summary":"Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire","headline":"Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Dia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUm1MV0p5RlZZWTdueEtmeUhXM1FSTGpBQUdrR2U5M2VIcDVuYmlSdU0zRkMyeHRySGY5U0YzNkpUNXlNWmpyU1FubjFuc1lVQlRmYkdkR3c1cVVqWnl0QXdZWHRlRUNFMko3STJPZ0pUY0lDdUdkdjgwR1JOUWc5bW5QWlVndzJSTWhKNm9KTXdyNXM4VDgzWWNpS2FCRjNWbWN2QU9CaDJzV0NrZGM1UEFxQ2U1TXlYTDFMeGlUVnM3QXpTNUtRZnRsR2w3S05teExhV20xZ0JtdTNRb29WeWdvLTk?oc=5","date":"2026-04-05","type":"pipeline","source":"ACCESS Newswire","summary":"Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress - ACCESS Newswire","headline":"Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Cong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQMVVZZkF6VmhqVkZEMTkxUmNoU1lqd1h1NnEzVXJONUhvU3lYTF94aHFHaERPUjNrQ1pjdm5SOUhkWXFJOEV3LTNNSWNhZ1RlNmlIT0gwbTBvYktJODc1bkdlTkNiVVJNa2UwOEI3TG8zRmljRTI1Nk1YdlkyVUVoc2dOWjlmMXhuTFJKc3hsdDlfVm92OTN5Mzh2dGtuMlNDQkxCMndiaThPMWhuV25LUzhWVE5DQ29udWc?oc=5","date":"2026-04-02","type":"trial","source":"Stock Titan","summary":"Children needing IV nutrition cut support 12%-37% in crofelemer study - Stock Titan","headline":"Children needing IV nutrition cut support 12%-37% in crofelemer study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOMVJVMGV6WERLTlNxS2lMekVHdjg4NXhKXzFuRXBXWG5VdmU0UEw5TVFpU01GS2NmcDVXRTJ0SGVhUjZJZkVIM0VUOExMRmtodHRIM1RHS0k0d3VIZlhmMVVVQWZBcExYSHhXcjhJOWpkc0pUbVJYUWhGemItWXpTb2lJZzQ1NVBuQmZLVUpTZS1YUlpCc0VXdDV0TVZ2QjFPLWtJ?oc=5","date":"2026-03-16","type":"trial","source":"newswire.com","summary":"Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression - newswire.com","headline":"Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1jRE9qS1RuTlY2RUVXZjJURkFlMnA0bmZrbVJJZEROeHpSNHBNazVTOFlkT3p3Q2kxZzBvVVhLOFA1ck16dXVaX19YeXA5RHVLU2lRN2JHLV9iWFQ5UHhGSjdNMnBkejdDR1ZraFEwRTU?oc=5","date":"2026-03-11","type":"pipeline","source":"Kansas City Star","summary":"Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts - Kansas City Star","headline":"Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFByU1pma1hnVU1WWmtER25QYk54Sm8wTG1DalBtaXA5V3pHbUVUaEpWWmdmcWhtY3FjWjNvcFAwa0ZxOVpXbk40VFBCTGNiWGhlc1BpR2FMZXRhMDdYQTdnTFIzOUxyMGQwdWhtdUpR?oc=5","date":"2026-03-02","type":"pipeline","source":"Lexington Herald Leader","summary":"Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend - Lexington Herald Leader","headline":"Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}